WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) recently reported its fourth-quarter and full-year 2025 results and disclosed a global settlement with Moderna valued at up to $2.25 billion, the company announced.
The settlement, reached with licensee Genevant Sciences, includes $950 million in upfront payments expected in July 2026 and up to $1.3 billion in contingent milestone payments tied to ongoing litigation outcomes.
The agreement resolves patent disputes related to lipid nanoparticle technology used in drug delivery. Arbutus said it will receive 20% of the upfront payment after costs and holds an equity stake of about 16% in Genevant.
The company said additional litigation involving Pfizer and BioNTech over similar technology remains ongoing.
Arbutus reported cash, cash equivalents, and marketable securities of $91.5 million as of December 31, 2025, down from $122.6 million a year earlier.
Total revenue for 2025 was $14.1 million, compared to $6.2 million in 2024, driven by the recognition of deferred revenue following the conclusion of a partnership with Qilu Pharmaceutical.
The company reported a net loss of $33.5 million for 2025, compared to $69.9 million the previous year.
Research and development expenses decreased to $25.2 million from $54.0 million, while general and administrative expenses declined to $15.9 million from $22.1 million, reflecting cost reductions and restructuring efforts.
Arbutus said two additional patients in its Phase 2a clinical trials of imdusiran achieved a functional cure for chronic hepatitis B, bringing the total to 10 patients.
The company also reported receiving a milestone payment related to its lipid nanoparticle licensing agreement with Alnylam for a treatment targeting hepatocellular carcinoma.
Arbutus said it is evaluating a potential return of capital to shareholders in the third quarter of 2026, contingent on receiving proceeds from the Moderna settlement.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.